Early and late effects of systemically administered 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on tyrosine hydroxylase activity in vitro and on tyrosine hydroxylation in tissue slices of mouse striatum.
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induces a parkinsonian-like state in humans and some animals. To compare the early biochemical abnormalities produced by this neurotoxin with late effects, we examined both in vitro tyrosine hydroxylase activity in striatal homogenates and in situ tyrosine hydroxylation in striatal tissue slices after single and repeated systemic injection of MPTP to mice. The acute administration of MPTP (30 mg/kg, s.c., 1 h prior to sacrifice) in mice resulted in a decrease of tyrosine hydroxylation in situ in tissue slices but not in vitro in homogenates. In contrast, repeated treatment of mice with MPTP (30 mg/kg, s.c. daily for 8 days) caused a decrease of tyrosine hydroxylase activity both in vitro in homogenates and in situ in tissue slices. These results suggest that MPTP inhibits tyrosine hydroxylation in dopaminergic neurons in an early stage and causes reduction of tyrosine hydroxylase itself after repeated administration.
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D000818:Animals; D003342:Corpus Striatum / Q000187:drug effects* / Q000378:metabolism; D003864:Depression, Chemical; D006900:Hydroxylation; D066298:In Vitro Techniques; D051379:Mice; D008810:Mice, Inbred C57BL; D011725:Pyridines / Q000494:pharmacology*; D014443:Tyrosine / Q000378:metabolism; D014446:Tyrosine 3-Monooxygenase / Q000037:antagonists & inhibitors*
D011725:Pyridines; D014443:Tyrosine; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D014446:Tyrosine 3-Monooxygenase